US Patent

US10961250 — Short-acting benzodiazepine salts and their polymorphic forms

Method of Use · Assigned to Paion UK Ltd · Expires 2027-07-10 · 1y remaining

Vulnerability score 66/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of preparing besylate salts of a specific compound, including their use as medicaments for various purposes.

USPTO Abstract

The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.

Drugs covered by this patent

remimazolam-besylate (REMIMAZOLAM BESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2968`	—	remimazolam-besylate

Patent Metadata

Patent number: US10961250
Jurisdiction: US
Classification: Method of Use
Expires: 2027-07-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Paion UK Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.